Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatiquinone in Friedreich's Ataxia
NCT07681713Phase 3Not yet recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 6
01
Overview
A Phase 3 trial of vatiquinone in Friedreich's ataxia (FA), sponsored by PTC Therapeutics, Inc.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
vatiquinone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT07681713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681713.